相关实验视频
Updated: Jul 6, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.3K
ID2促进瘤的进展和甲状腺癌的转移
Zhongming Deng1, Min Xu2, Zhenghua Ding1
1Department of General Surgery, Xiangyang No.1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China.
Endocrine
|January 10, 2024
概括
抑制DNA结合2 (ID2) 通过激活PI3K/Akt路径,促进甲状腺癌的进展. ID2可以作为改善癌症治疗疗效的生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 抑制DNA结合2的抑制剂 (ID2) 涉及到瘤的进展,入侵,转移和茎状.
- 异常的ID2表达与多种癌症类型的不良预后相关.
- ID2在甲状腺癌发病过程中的特定作用在很大程度上仍未被定义.
研究的目的:
- 阐明ID2在甲状腺癌中的功能和临床相关性.
- 为了研究底层的分子机制ID2介导的癌细胞行为.
- 探索ID2作为一种潜在的治疗生物标志物.
主要方法:
- 利用TCGA数据库进行临床相关性分析.
- 使用生物信息学工具 (GO,KEGG,TIMER) 来进行路径预测.
- 进行了体外功能测定 (扩散,入侵,茎状) 和分子分析 (WB,RT-qPCR,IHC).
主要成果:
- 在恶性瘤细胞中,ID2显著过度表达,促进了扩散和入侵.
- ID2通过激活PI3K/Akt信号通路,对Akt抑制产生抗性.
- ID2可以调节下游的增殖标志物,上皮细胞-介质细胞过渡 (EMT) 和干性.
结论:
- ID2通过PI3K/Akt路径驱动甲状腺癌细胞的增殖,迁移,EMT和干细胞.
- ID2 影响癌症免疫反应,并可作为治疗疗效的生物标志物.
- 向ID2可以提高化疗,向治疗和免疫治疗的结果.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Synthesis and Regulation of Thyroid Hormones
4.6K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
4.6K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K

